Delivery Order SPE2DB24D1205-SPE2DB25FCXLN
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,896.60 for MENQUADFI vial 0.5ML pharmaceutical products on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed in Conshohocken, Pennsylvania, where the contractor maintains its corporate headquarters. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $5,085.08 to AmerisourceBergen Drug Corp for MENQUADFI VIAL 0.5ML, a pharmaceutical product, with a completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5ML) with a ceiling value of $8,254.21 under a firm fixed-price contract type. The award was made on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a competitively awarded, non-set-aside delivery order issued under...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,452.88 by the Defense Logistics Agency (DLA) for MENQUADFI VIAL 0.5ML, a pharmaceutical product. The contract is competitively awarded with no set-aside designation and operates under a firm fixed price structure, with an ultimate completion date of August 4, 2025. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for MENQUADFI VIAL 0.5ML, a pharmaceutical product, with a ceiling value of $1,452.88. This firm fixed price delivery order is not set-aside and is scheduled for completion by August 14, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,179.32 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without set-aside designation, reflects a competitively awarded transaction under the company's broader pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $2,905.76 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5ML) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price contract is being performed in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. The delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,179.32 to AmerisourceBergen Drug Corp for MENQUADFI VIAL 0.5ML, a pharmaceutical product. This firm fixed price contract, awarded on September 2, 2025, with a completion date of September 3, 2025, represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was not designated as a set-aside contract and will be performed at the contractor's location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,452.90 to AmerisourceBergen Drug Corp for MENQUADFI VIAL 0.5ML on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract was issued with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $2,905.80 to AmerisourceBergen Drug Corp for MENQUADFI vial 0.5ML on September 11, 2025, with completion targeted for September 12, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXLNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,542.36 to AmerisourceBergen Drug Corp for MENQUADFI VIAL 0.5ML, a pharmaceutical product to be delivered to Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price contract was executed on June 5, 2025, with an ultimate completion date of June 6, 2025, indicating a rapid fulfillment requirement typical of medical supply chain operations. The award represents a child contract under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. This delivery order falls under AmerisourceBergen's comprehensive Indefinite Delivery Contract (SPE2DX) valued at $999,999,999.00 and extending through December 2026, which serves as a global pharmaceutical support vehicle for the Defense Logistics Agency's medical supply chain. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, regularly fulfills federal medical procurement needs for military and veteran healthcare systems through competitively awarded delivery orders covering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular award underscores the company's role as a critical vendor supporting the Defense Health Agency and other federal healthcare systems through flexible contract mechanisms designed to meet dynamic military medical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 6/5/25 |